Pre-made Tidutamab benchmark antibody ( Bispecific Mixed mAb and scFv, anti-SSTR2;CD3E therapeutic antibody, Anti-T3E/TCRE/IMD18/CD3epsilon Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Tidutamab (formerly XmAb 18087) is a humanised, Fc domain-containing, bispecific monoclonal antibody targeting somatostatin receptor 2 (SSTR2) and a cytotoxic T-cell binding domain (CD3), being developed by Xencor, for the treatment of neuroendocrine tumours (NET) and gastrointestinal stromal tumours (GIST).
| Products Name (INN Index) | Pre-Made Tidutamab biosimilar, Bispecific Mixed mAb and scFv, Anti-SSTR2;CD3E Antibody: Anti-T3E/TCRE/IMD18/CD3epsilon therapeutic antibody |
|---|---|
| INN Name | Tidutamab |
| Target | SSTR2,CD3E |
| Format | Bispecific Mixed mAb and scFv |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Discontinued |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2018 |
| Year Recommended | 2019 |
| Companies | ICON,Xencor |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Gastrointestinal stromal tumours,Neuroendocrine tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | SSTR2,CD3E |
| Package |
